Perspectives on Developing Small Molecule Inhibitors Targeting HIV-1 Integrase

Author(s): J. J. Tan, C. Liu, X. H. Sun, X. J. Cong, L. M. Hu, C. X. Wang, X. J. Liang.

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 12 , Issue 9 , 2012

Become EABM
Become Reviewer


HIV-1 integrase (IN) is a crucial enzyme in the life cycle of HIV-1 and also a validated target for developing anti-HIV inhibitors. Recent progress in drug design has significantly accelerated the development of anti-AIDS IN inhibitors. A large amount of novel inhibitors that interact specifically with IN were developed along with the expanding and application of methods to drug design. This article reviewed the anti-HIV IN inhibitors discovered by the rational drug design approaches in the recent 5-year.

Keywords: de novo drug design, HIV, integrase inhibitors, ligand-based drug design, pharmacophore, receptor-based drug design, virtual screening, Genetic Algorithms, DOCK

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [875 - 889]
Pages: 15
DOI: 10.2174/138955712800959107
Price: $58

Article Metrics

PDF: 13